The popular drug, sold by Eli Lilly and Company under the brand name Mounjaro, has been at the center of many cardiology trials over the years. It is now the first dual GIP and GLP-1 hormone receptor agonist approved by the FDA for this indication.Read More
FDA approves tirzepatide for reducing cardiovascular risk in adults with type 2 diabetes
